| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-4241
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-4291
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-4208
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-4283
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-686
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate |
2010-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_798438aa35948c75227c2b89734e0d41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49d7fc3dcfbcc3b409ccb5adfe845743
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6fb26851a75de750d219e6427b28c65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_579d9f9367f2828269a72c9e204db963 |
| publicationDate |
2018-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2642295-C2 |
| titleOfInvention |
Analysis of identification of antibodies specific to therapeutic antibodies against ige, and their application in anaphylaxis |
| abstract |
FIELD: biotechnology. n SUBSTANCE: methods for detection of a human IgE isotype antibody against omalizumab are provided. Sets, methods for identification of a patient at risk of an anaphylactic reaction to omalizumab, and a method for treatment of a patient with an IgE-mediated disorder are also contemplated. n EFFECT: invention allows timely detection of allergic reactions to omalizumab and can be used in therapy and prevention of anaphylaxis. n 52 cl, 27 dwg, 7 tbl, 7 ex |
| priorityDate |
2009-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |